Circulating immune complexes and chemotherapy response in patients with head and neck cancer

B. A. Blazar, Marvin P. Fried, M. Strome, J. R. Clark, P. Sereno, S. Rodliff, D. Caminear

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

An assay which could prospectively predict a response to chemotherapy prior to instituting therapy would be beneficial, especially for nonresponders. We evaluated at random a total of 50 patients with previously untreated stage III and IV head and neck squamous cell carcinoma for T-cell subsets and levels of circulating immune complexes (CIC). Of this group 23 patients had induction chemotherapy as their first modality of treatment. These patients received standard protocols of therapy consisting of cisplatin, 5-fluorouracil, methotrexate, and bleomycin. Of the laboratory measures assessed, only CIC correlated with clinical response to chemotherapy [no response (NR), partial response (PR), complete response (CR)] at the completion of the induction period (two to four cycles). Levels of CIC were determined by a polyethylene glycol (PEG) precipitation assay, and measured by spectrophotometry at 280 nm. In our population of all head and neck cancer patients, CIC were elevated (mean ± SD values: 0.475 ± 3.8 compared with controls: 0.184 ± 0.07). In the NR group, the mean ± SD was 0.707 ± 0.43 (P = 0.001). Complete responders had a mean value of 0.332 ± 0.21; partial responders had a mean value of 0.255 ± 0.13. On the basis of the values determined, patients with markedly elevated levels of CIC would be predicted to respond poorly, or not all, to current induction chemotherapy protocols.

Original languageEnglish (US)
Pages (from-to)431-436
Number of pages6
JournalHead and Neck
Volume11
Issue number5
StatePublished - 1989
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Antigen-Antibody Complex
Drug Therapy
Induction Chemotherapy
Spectrophotometry
Bleomycin
T-Lymphocyte Subsets
Methotrexate
Fluorouracil
Cisplatin
Therapeutics
Population

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Blazar, B. A., Fried, M. P., Strome, M., Clark, J. R., Sereno, P., Rodliff, S., & Caminear, D. (1989). Circulating immune complexes and chemotherapy response in patients with head and neck cancer. Head and Neck, 11(5), 431-436.

Circulating immune complexes and chemotherapy response in patients with head and neck cancer. / Blazar, B. A.; Fried, Marvin P.; Strome, M.; Clark, J. R.; Sereno, P.; Rodliff, S.; Caminear, D.

In: Head and Neck, Vol. 11, No. 5, 1989, p. 431-436.

Research output: Contribution to journalArticle

Blazar, BA, Fried, MP, Strome, M, Clark, JR, Sereno, P, Rodliff, S & Caminear, D 1989, 'Circulating immune complexes and chemotherapy response in patients with head and neck cancer', Head and Neck, vol. 11, no. 5, pp. 431-436.
Blazar BA, Fried MP, Strome M, Clark JR, Sereno P, Rodliff S et al. Circulating immune complexes and chemotherapy response in patients with head and neck cancer. Head and Neck. 1989;11(5):431-436.
Blazar, B. A. ; Fried, Marvin P. ; Strome, M. ; Clark, J. R. ; Sereno, P. ; Rodliff, S. ; Caminear, D. / Circulating immune complexes and chemotherapy response in patients with head and neck cancer. In: Head and Neck. 1989 ; Vol. 11, No. 5. pp. 431-436.
@article{1efbbddcfcca4f77a7f75b8ff6a5e1bc,
title = "Circulating immune complexes and chemotherapy response in patients with head and neck cancer",
abstract = "An assay which could prospectively predict a response to chemotherapy prior to instituting therapy would be beneficial, especially for nonresponders. We evaluated at random a total of 50 patients with previously untreated stage III and IV head and neck squamous cell carcinoma for T-cell subsets and levels of circulating immune complexes (CIC). Of this group 23 patients had induction chemotherapy as their first modality of treatment. These patients received standard protocols of therapy consisting of cisplatin, 5-fluorouracil, methotrexate, and bleomycin. Of the laboratory measures assessed, only CIC correlated with clinical response to chemotherapy [no response (NR), partial response (PR), complete response (CR)] at the completion of the induction period (two to four cycles). Levels of CIC were determined by a polyethylene glycol (PEG) precipitation assay, and measured by spectrophotometry at 280 nm. In our population of all head and neck cancer patients, CIC were elevated (mean ± SD values: 0.475 ± 3.8 compared with controls: 0.184 ± 0.07). In the NR group, the mean ± SD was 0.707 ± 0.43 (P = 0.001). Complete responders had a mean value of 0.332 ± 0.21; partial responders had a mean value of 0.255 ± 0.13. On the basis of the values determined, patients with markedly elevated levels of CIC would be predicted to respond poorly, or not all, to current induction chemotherapy protocols.",
author = "Blazar, {B. A.} and Fried, {Marvin P.} and M. Strome and Clark, {J. R.} and P. Sereno and S. Rodliff and D. Caminear",
year = "1989",
language = "English (US)",
volume = "11",
pages = "431--436",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Circulating immune complexes and chemotherapy response in patients with head and neck cancer

AU - Blazar, B. A.

AU - Fried, Marvin P.

AU - Strome, M.

AU - Clark, J. R.

AU - Sereno, P.

AU - Rodliff, S.

AU - Caminear, D.

PY - 1989

Y1 - 1989

N2 - An assay which could prospectively predict a response to chemotherapy prior to instituting therapy would be beneficial, especially for nonresponders. We evaluated at random a total of 50 patients with previously untreated stage III and IV head and neck squamous cell carcinoma for T-cell subsets and levels of circulating immune complexes (CIC). Of this group 23 patients had induction chemotherapy as their first modality of treatment. These patients received standard protocols of therapy consisting of cisplatin, 5-fluorouracil, methotrexate, and bleomycin. Of the laboratory measures assessed, only CIC correlated with clinical response to chemotherapy [no response (NR), partial response (PR), complete response (CR)] at the completion of the induction period (two to four cycles). Levels of CIC were determined by a polyethylene glycol (PEG) precipitation assay, and measured by spectrophotometry at 280 nm. In our population of all head and neck cancer patients, CIC were elevated (mean ± SD values: 0.475 ± 3.8 compared with controls: 0.184 ± 0.07). In the NR group, the mean ± SD was 0.707 ± 0.43 (P = 0.001). Complete responders had a mean value of 0.332 ± 0.21; partial responders had a mean value of 0.255 ± 0.13. On the basis of the values determined, patients with markedly elevated levels of CIC would be predicted to respond poorly, or not all, to current induction chemotherapy protocols.

AB - An assay which could prospectively predict a response to chemotherapy prior to instituting therapy would be beneficial, especially for nonresponders. We evaluated at random a total of 50 patients with previously untreated stage III and IV head and neck squamous cell carcinoma for T-cell subsets and levels of circulating immune complexes (CIC). Of this group 23 patients had induction chemotherapy as their first modality of treatment. These patients received standard protocols of therapy consisting of cisplatin, 5-fluorouracil, methotrexate, and bleomycin. Of the laboratory measures assessed, only CIC correlated with clinical response to chemotherapy [no response (NR), partial response (PR), complete response (CR)] at the completion of the induction period (two to four cycles). Levels of CIC were determined by a polyethylene glycol (PEG) precipitation assay, and measured by spectrophotometry at 280 nm. In our population of all head and neck cancer patients, CIC were elevated (mean ± SD values: 0.475 ± 3.8 compared with controls: 0.184 ± 0.07). In the NR group, the mean ± SD was 0.707 ± 0.43 (P = 0.001). Complete responders had a mean value of 0.332 ± 0.21; partial responders had a mean value of 0.255 ± 0.13. On the basis of the values determined, patients with markedly elevated levels of CIC would be predicted to respond poorly, or not all, to current induction chemotherapy protocols.

UR - http://www.scopus.com/inward/record.url?scp=0024340426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024340426&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 431

EP - 436

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

IS - 5

ER -